INTRODUCTION
SCA is a single-gene mutation genetic disease caused by change of Glu6Val at the hemoglobin beta chain gene and characterized by high variable clinical complications 1 . The skeletal manifestations of sickle cell disease are the result of changes in bone and bone marrow caused by the chronic tissue hypoxia that is exacerbated by episodic occlusion of the microcirculation by the abnormal sickle cells. Furthermore, the occurrence of osteonecrosis is under the control of some modifier gene. BMP6 (Bone morphogenetic protein) has been reported as associated with osteonecrosis in sickle cell anemia (SCA) (ref.
2 ). Bone morphogenetic proteins (BMPs) are members of the TGF-beta superfamily of molecules. They are multifunctional cytokines involved in many aspects of tissue development and morphogenesis. BMP6 is involved in inflammatory processes and is important for bone formation and, in association with parathyroid hormone (PTH) and vitamin D, appears to be involved in inducing bone development by human bone marrow-derived mesenchymal stem cells 3 . BMP6 promotes osteoblast differentiation from mesenchymal stem cells [4] [5] studied the role of BMP6 in cartilage homeostasis; they discovered an essential involvement of this gene in the repair/maintenance of human articular cartilage. In sickle cell osteonecrosis, the progressive degeneration of the bone eventually led to its collapse and destruction of articular cartilage, supporting a role of BMP6 in the pathogenesis of this complication. Indeed, Baldwin et al. 6 have reported the role of rs267196, rs267201 and rs449853 in the occurrence of osteonecrosis in sickle cell disease.
Herein, we aimed to explore the implication of four known polymorphisms of BMP6: rs408505, rs449853, rs267201 and rs267196 in osteonecrosis among SCA patients.
MATERIAL AND METHODS

Material
100 sickle cell patients were involved in this study. Patients were selected on the basis of homozygosity for β s -globin gene. Demographic, hematological and clinical data of subjects studied are summarized in Table 1 .
METHODS
Clinical events
Data and clinical events were taken from the patient's history via search of the clinical registry with radiologically documented osteonecrosis. Patients chosen in this study have osteonecrosis of the head of the femur.
Laboratory methods
Diagnosis of sickle cell patient is performed using cation-exchange high performance liquid chromatography (HPLC) (D10 Biorad) and further confirmation by means of molecular diagnosis by restriction fragment length polymorphism (RFLP) using DdeI as previously described by Romana 2000 7 . Biochemical data were averaged for each patient in steady state (at least three values). We determined total and fetal hemoglobin (HbF) concentrations (D10, Biorad), and reticulocyte count and other hematologic parameters using (ABX pentra 60c+).
Genotyping of BMP6 polymorphisms
Genomic DNA was isolated from white blood cells of total blood using standard method (phenol/chloroform). A polymerase chain reaction (PCR) was performed using 4 couple of primers as described in Table 2 PCR products were then purified and doubly sequenced (forward and reverse) by ABI PRISM Big Dye Terminator on ready reaction kit (Applied Biosystems, Foster City, CA, USA) and an ABI 310 DNA sequencer (PEApplied Biosystems, Foster City, USA).
Statistical analysis
The demographic and hematologic data were normally distributed. The Hardy-Weinberg equilibrium was tested using the software package Arlequin (version 3.01). Genetic differences between cases and controls were evaluated applying tests to genotypic or allelic contingency tables (Compare 2, version 1.02). We used Fisher's exact test and chi-squared tests where appropriate.
RESULTS
The sample of patients was divided into two groups according to the presence or absence of osteonecrosis. Hematologic data such as hemoglobin and other parameters suggested similar hemolytic rates in these groups ( Table 1 ). The two groups of patients stratified accordingly to the occurrence of osteonecrosis were compared for age, sex ratio and hematological data including HbF. No significant association was found.
For each polymorphism the samples were found to be in Hardy-Weinberg equilibrium. As for BMP6 polymorphisms, the distribution of genotypes and alleles was analyzed for all patients (Table 3) . Indeed, for the polymorphisms rs408505 and rs449853 the repartition of genotypes and alleles between the two groups of patients showed no significant association. Further, the analysis of genetic profile of rs267196 showed that the major genotype in SCA patients without osteonecrosis is the normal TT (50.62%). Although it is the TA (63.16%) among SCA with osteonecrosis. As for rs267201, our results showed that the major genotype in SCA patients without osteonecrosis was the normal AA (53.09%) and AG (57.9%) in SCA patients with osteonecrosis. The distribution of genotypes between SCA patients according to the presence or absence of osteonecrosis revealed that patients carried genotype TA of rs267196 and genotype AG of rs267201 present a risk factor for developing osteonecrosis OR=1.317 and OR=1.3 respectively ( Table 3 ). The analysis of allelic distribution showed the association of variant A of rs267196 and variant G of rs267201 with the risk of developing osteonecrosis (Table 3) . Interestingly, the stratification of genotypes found using logistic regression according to the presence or absence of osteonecrosis revealed the association of both genotypes TA of rs267196 and AG of rs267201 with osteonecrosis and thus appears to present a risk factor for the occurrence of osteonecrosis (P=0.009) ( Table 4 ). The repartition of genetic profile according to hematological parameters showed no significant differences between the groups with risk genotype and whose with normal genotype (Table 5) .
DISCUSSION
Osteonecrosis is a common sequela of sickle cell disease; studies suggest that some modifier genes are found to be associated with this complication 2 . Genetic association studies, which attempt to link gene polymorphisms with selected complications, highlighted some variants of candidate gene. We examined the association of single nucleotide polymorphisms (SNPs) in candidate gene of bone metabolism with osteonecrosis in patients with SCA namely BMP6. This gene is important in bone morphology. BMP-6 was also shown to be associated with other vascular complications in SCD such as priapism 8 and stroke 9 , suggesting a common underlying molecular basis for these vascular complications.
In the current study, 4 SNPs in BMP6 were genotyped, and significant associations with osteonecrosis were observed with 2 SNPs namely: rs267196 and rs267201. As for rs408505 and rs449853 of BMP6 gene, no significant association was found among SCA patients. Our findings show that the patients who carried genotype TA of rs267196 and genotype AG of rs267201 present a high risk factor for developing osteonecrosis RR=1.317 and RR=1.3 respectively. Our results showed a significant association between the alleles A of rs267196 and G of rs267201 and osteonecrosis P=0.0023; RR=2.42 and P=0.041; RR=2.24 respectively. Interestingly, SCA patients with the combined genotype TA/AG were found to be at higher risk of developing osteonecrosis (P=0.009). Only one study has identified the latter polymorphisms as associated with osteonecrosis 6 . Whereas Ulug et al. 10 found no association between rs267196 and avascular necrosis among SCA patients. Two studies have described the implication of BMP6 polymorphisms in patients with sickle cell disease including SS, Sβ + , Sβ 0 and SC. By cons, in our study we focused on SS patients. The mechanisms by which rs267196 and rs267201 in BMP6 gene predispose sickle cell patients to osteonecrosis complication are unknown.
Elucidating the genetic basis for the development of sickle cell osteonecrosis may provide new insight into the pathogenesis in SCA patients and hence provide treatement options, which are still limited. As for BMP6, regulating the activity of the TGF-β pathway to modulate its effects on bone may be possible 11 . Ultimately, rs267196 and rs267201 of BMP6 may be considered as a reliable biomarker for predicting at an early age, patients at high risk for osteonecrosis, and thus allow earlier and more effective therapeutic intervention.
ABBREVIATIONS
BMP6, bone morphogenetic protein6; CI, confidence interval; OR, odds ratio; P, index of significance; RR, relative risk; SCA, Sickle Cell Anemia.
